论文部分内容阅读
抗体介导的排斥反应(AMR)是肾移植术后常见的严重并发症。近年来大量研究探讨了抗体特征与临床表现、移植肾预后之间的关系。针对非抗HLA抗体的研究更加明确了这些抗体在肾移植中的意义和作用。AMR的诊断也在经历了巨大变革。与排斥诊断、预后相关的生物学标志物不断被发现及验证。小样本研究报道硼替佐米、利妥昔单抗、C1q单抗治疗AMR的疗效,初步表明这些药物的有效性和安全性。此外,在动物实验中多种药物显示了良好的预防/治疗AMR的效能。
Antibody-mediated rejection (AMR) is a common and serious complication after renal transplantation. In recent years, a large number of studies explored the relationship between antibody characteristics and clinical manifestations, renal allograft prognosis. The study of non-anti-HLA antibodies further clarified the significance and role of these antibodies in renal transplantation. The diagnosis of AMR is undergoing tremendous change. Biological markers that are associated with rejection and prognosis are continually found and validated. Small sample reports of bortezomib, rituximab, C1q monoclonal antibody in the treatment of AMR efficacy, a preliminary indication of the effectiveness of these drugs and safety. In addition, various drugs have shown good efficacy in the prevention / treatment of AMR in animal experiments.